Format
Sort by

Send to

Choose Destination

Search results

Items: 13

1.

Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.

Bønaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygård O, Nilsen DW, Kløw NE, Uchto M, Trovik T, Bendz B, Stavnes S, Bjørnerheim R, Larsen AI, Slette M, Steigen T, Jakobsen OJ, Bleie Ø, Fossum E, Hanssen TA, Dahl-Eriksen Ø, Njølstad I, Rasmussen K, Wilsgaard T, Nordrehaug JE; NORSTENT Investigators..

N Engl J Med. 2016 Sep 29;375(13):1242-52. doi: 10.1056/NEJMoa1607991.

2.

The Austrian transcatheter aortic valve implantation (TAVI) Registry--3 years' data.

Zweiker D, Maier R, Lamm G, Maurer E, Heigert M, Neunteufl T, Zeindlhofer E, Grund M, Aichinger J, Huber K, Schneider J, Pollak J, Luha O, Zweiker R; Austrian Society of Cardiology, Committee on Interventional Cardiology..

Int J Cardiol. 2014 Nov 15;177(1):114-6. doi: 10.1016/j.ijcard.2014.09.096. No abstract available.

PMID:
25499351
3.

Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.

Camenzind E, Boersma E, Wijns W, Mauri L, Rademaker-Havinga T, Ordoubadi FF, Suttorp MJ, Al Kurdi M, Steg PG; PROTECT Steering Committee and Investigators..

Eur Heart J. 2014 Aug 1;35(29):1932-48. doi: 10.1093/eurheartj/ehu084.

4.

Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial.

Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Boersma E, Vranckx P, McFadden E, Serruys PW, O'Neil WW, Jorissen B, Van Leeuwen F, Steg PG; PROTECT Steering Committee and Investigators..

Lancet. 2012 Oct 20;380(9851):1396-405. doi: 10.1016/S0140-6736(12)61336-1.

PMID:
22951082
5.

[Transcatheter aortic valve replacement: when should it be used in aortic stenosis?].

Motloch LJ, Reda S, Rottlaender D, Heigert M, Hoppe UC.

Wien Med Wochenschr. 2012 Aug;162(15-16):340-8. doi: 10.1007/s10354-012-0136-6. Review. German.

PMID:
22864727
6.

Rehospitalization rates after transcatheter aortic valve implantation.

Hammerer M, Schuler J, Altenberger J, Kraus J, Prinz E, Matzinger M, Pichler M, Heigert M.

Wien Klin Wochenschr. 2012 Jan;124(1-2):45-52. doi: 10.1007/s00508-011-0075-z.

PMID:
22025000
7.

The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.

Grube E, Chevalier B, Smits P, Džavík V, Patel TM, Mullasari AS, Wöhrle J, Stuteville M, Dorange C, Kaul U; SPIRIT V Investigators..

JACC Cardiovasc Interv. 2011 Feb;4(2):168-75. doi: 10.1016/j.jcin.2010.11.006.

8.

Different pattern of regional metabolic abnormalities in Takotsubo cardiomyopathy as evidenced by F-18 FDG PET-CT.

Rendl G, Rettenbacher L, Keinrath P, Altenberger J, Schuler J, Heigert M, Pichler M, Pirich C.

Wien Klin Wochenschr. 2010 Mar;122(5-6):184-5. doi: 10.1007/s00508-010-1356-7. No abstract available.

PMID:
20361383
9.

Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.

Camenzind E, Wijns W, Mauri L, Boersma E, Parikh K, Kurowski V, Gao R, Bode C, Greenwood JP, Gershlick A, O'Neill W, Serruys PW, Jorissen B, Steg PG; PROTECT Steering Committee and Investigators..

Am Heart J. 2009 Dec;158(6):902-909.e5. doi: 10.1016/j.ahj.2009.10.002.

PMID:
19958855
10.

2-year results of the AUTAX (Austrian Multivessel TAXUS-Stent) registry beyond the SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) study.

Gyöngyösi M, Christ G, Lang I, Kreiner G, Sochor H, Probst P, Neunteufl T, Badr-Eslam R, Winkler S, Nyolczas N, Posa A, Leisch F, Karnik R, Siostrzonek P, Harb S, Heigert M, Zenker G, Benzer W, Bonner G, Kaider A, Glogar D; AUTAX Investigators..

JACC Cardiovasc Interv. 2009 Aug;2(8):718-27. doi: 10.1016/j.jcin.2009.05.019.

11.

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators..

N Engl J Med. 2009 Mar 5;360(10):961-72. doi: 10.1056/NEJMoa0804626. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.

12.

Small vessel stenting with cobalt-chromium stents (Arthos Pico) in a real world setting.

Strehblow C, Gyöngyösi M, Zenker G, Wallner H, Heigert M, Siostrzonek P, Tischler R, Probst P, Lang I, Sochor H, Glogar D.

Coron Artery Dis. 2007 Jun;18(4):305-11.

PMID:
17496495
13.

Enoxaparin in elective percutaneous coronary intervention.

Schuler J, Altenberger J, Heigert M.

N Engl J Med. 2006 Dec 28;355(26):2789-90; author reply 2790-1. No abstract available.

PMID:
17193723
Items per page

Supplemental Content

Loading ...
Support Center